Methods for identifying a cancer patient, such as a breast cancer patient, suitable for treatment with a 4-anilinoquinazoline kinase inhibitor, such as lapatinib, and an AKT inhibitor, comprising detecting modulated expression of HER2 (ERBB2) and SASH1 or protein encoded thereof and detecting PIK3CA mutation status. High levels of expression in HER2 and high levels of SASH1 and/or positive PIK3CA mutation status indicate a patient that is suitable for treatment with a 4-anilinoquinazoline kinase inhibitor, such as lapatinib and an AKT inhibitor.
STATEMENT OF GOVERNMENTAL SUPPORT
 The invention described was made with government support under Contract No. DE-AC02-05CH11231 awarded by the U.S. Department of Energy, under Work for Others Agreement No. LB06002417, and under Grant No. CA 126551 SPORE grant and Grant No. P50 CA58207 awarded by the National Institutes of Health. The government has certain rights in this invention.